Exploring the Role of CDK4/6 Inhibitors in HR+ HER2- Breast Cancer: From the Adjuvant to the Metastatic Setting

Novartis Pharma Schweiz AG

Wednesday, 19.11.2025, 12:30 - 13:30, Bosten 1-2

Chemotherapy-free first line treatment in common EGFR mutated NSCLC - Improving patient outcomes and simplify patient management

Johnson & Johnson

Wednesday, 19.11.2025, 12:30 - 13:30, Shanghai 1-2

Advancing the Standard: Anti-BCMA Modalities in the Management of Early Multiple Myeloma Relapse

GSK

Wednesday, 19.11.2025, 12:30 - 13:30, Shanghai 3-4

Advancing treatment for ES-SCLC: innovations in precision medicine

Amgen

Wednesday, 19.11.2025, 12:30 - 13:30, Delhi

Expertenrunde zur CLL: Personalisierte Therapiestrategien für die klinische Praxis

Abbvie

Thursday, 20.11.2025, 12:30 - 13:30, Boston 1-2

Unlocking the Potential of ADCs: Novel Approaches in Gynecologic Cancers

Abbvie

Thursday, 20.11.2025, 12:30 - 13:30, Shanghai 1-2

Treatment Strategies in Multiple Myeloma: Focus on Clinical Cases

Pfizer

Thursday, 20.11.2025, 12:30 - 13:30, Shanghai 3-4

Focus on QoL and tolerability in CML-CP: Status, limitations and latest advances Quality of life and tolerability updates from the asciminib Phase 3 study program

Novartis Pharma Schweiz AG

Thursday, 20.11.2025, 12:30 - 13:30, Kairo 1-2

CLL Launch Symposium

Eli Lilly and Company

Friday, 21.11.2025, 12:30 - 13:30, Boston 1-2

Advancing Outcomes with Data-Driven Insights in Solid Tumors (Breast & Lung Cancer)

Pfizer

Friday, 21.11.2025, 12:30 - 13:30, Shanghai 1-2

Logo will follow

From bench to bedside: Clinical use of the CRISPR/Cas technology

Vertex Pharmaceuticals GmbH

Friday, 21.11.2025, 12:30 - 13:30, Shanghai 3-4